Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis
Recent Posts
- Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis
- Sun Pharma Comes on Board as Principal Sponsor and Health Partner of Royal Challengers Bengaluru (RCB) for T20 Season 2026
- Sun Pharma reports Q3FY26 results
- Sun Pharma receives DCGI approval to manufacture and market generic semaglutide injection in India for chronic weight management
- Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
Recent Comments